Table 1.
Patients’ clinico-pathological characteristics at baseline.
| Characteristics | Patients N = 34%) |
NP N = 16%) |
P N = 18%) |
|---|---|---|---|
| Gender | |||
| Male | 23 (67.6) | 12 (75.0) | 11 (61.1) |
| Female | 11 (32.4) | 4 (25.0) | 7 (38.9) |
| Age years, median (range) | 72 (44–84) | 72.5 (58–82) | 72 (44–84) |
| ECOG performance status | |||
| 0 | 14 (41.2) | 8 (5.0) | 6 (33.3) |
| 1 | 17 (5.0) | 7 (43.8) | 10 (55.6) |
| 2 | 3 (8.8) | 1 (6.2) | 2 (11.1) |
| Smoker | |||
| Never | 7 (2.6) | 1 (6.2) | 6 (33.3) |
| Former | 20 (58.8) | 11 (68.8) | 9 (5.0) |
| Current | 7 (2.6) | 4 (25) | 3 (16.7) |
| Histology | |||
| Adenocarcinoma | 25 (73.5) | 11 (68.8) | 14 (77.8) |
| Squamous Carcinoma | 9 (26.5) | 5 (31.3) | 4 (22.2) |
| EGFR Status | |||
| Mutated | 1 (2.9) | 0 (.0) | 1 (5.6) |
| Wild Type | 33 (97.1) | 16 (1.0) | 17 (94.4) |
| PDL1% | |||
| <1% | 3 (8.8) | 1 (6.2) | 2 (11.1) |
| ≥1%-<50% | 15 (44.1) | 5 (31.3) | 10 (55.6) |
| ≥50% | 16 (47.1) | 10 (62.5) | 6 (33.3) |
| Immunotherapy Agent | |||
| Pembrolizumab | 16 (47.1) | 10 (62.5) | 6 (33.3) |
| Nivolumab | 14 (41.2) | 4 (25.0) | 10 (55.6) |
| Atezolizumab | 4 (11.7) | 2 (12.5) | 2 (11.1) |
| Line of immunotherapy | |||
| First | 16 (47.1) | 10 (62.5) | 6 (33.3) |
| Second | 18 (52.9) | 6 (37.5) | 12 (66.7) |
Abbreviations: N: number; NP: non progressor; P: Progressor; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; PD-L1: programmed death-ligand 1.